Eloralintide
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
Eli Lilly · Phase 2 · Active, not recruiting · Enrollment 200
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Macupatide (Macupatide + Eloralintide Placebo) | n/r | n/r | n/r | n/r |
| Eloralintide (Elorlintide + Macupatide Placebo) | n/r | n/r | n/r | n/r |
| Macupatide + Eloralintide | n/r | n/r | n/r | n/r |
| Placebo (Macupatide Placebo + Elorlintide Placebo) | n/r | n/r | n/r | n/r |
Not shown
- Macupatide (Macupatide + Eloralintide Placebo): endpoint not reported
- Eloralintide (Elorlintide + Macupatide Placebo): endpoint not reported
- Macupatide + Eloralintide: endpoint not reported
- Placebo (Macupatide Placebo + Elorlintide Placebo): endpoint not reported